Vertex Historical Income Statement
VRTX Stock | USD 404.91 4.99 1.25% |
Historical analysis of Vertex Pharmaceuticals income statement accounts such as Total Revenue of 10.3 B, Gross Profit of 9 B, Other Operating Expenses of 6.4 B or Operating Income of 3.9 B can show how well Vertex Pharmaceuticals performed in making a profits. Evaluating Vertex Pharmaceuticals income statement over time to spot trends is a great complementary tool to traditional technical analysis and can indicate the direction of Vertex Pharmaceuticals's future profits or losses.
Financial Statement Analysis is much more than just reviewing and examining Vertex Pharmaceuticals latest accounting reports to predict its past. Macroaxis encourages investors to analyze financial statements over time for various trends across multiple indicators and accounts to determine whether Vertex Pharmaceuticals is a good buy for the upcoming year.
Vertex |
About Vertex Income Statement Analysis
Vertex Pharmaceuticals Income Statement consists of revenues and expenses along with the resulting net income or loss. It represents the profit for the accounting period attributable to Vertex Pharmaceuticals shareholders. The income statement also shows Vertex investors and management if the firm made money during the period reported. The result of an income statement is the net income that is calculated after subtracting the expenses from revenue. It is essential to investors both as an absolute measure as well as earnings per share (i.e., EPS).
Vertex Pharmaceuticals Income Statement Chart
Vertex Pharmaceuticals Income Statement is one of the three primary financial statements used for reporting Vertex's overall financial performance over a current year or for a given accounting period. An Income Statement sometimes referred to as the statement of Vertex Pharmaceuticals revenue and expense. Vertex Pharmaceuticals Income Statement primarily focuses on the company's revenues and expenses during a particular period.
At this time, Vertex Pharmaceuticals' Cost Of Revenue is fairly stable compared to the past year. Income Before Tax is likely to rise to about 4.6 B in 2024, whereas Interest Expense is likely to drop slightly above 28.9 M in 2024. Add Fundamental
Total Revenue
Total revenue comprises all receipts Vertex Pharmaceuticals generated from the sale of its products or services. The total amount of income generated by the sale of goods or services related to the company's primary operations.Gross Profit
Gross profit is a required income statement account that reflects total revenue of Vertex Pharmaceuticals minus its cost of goods sold. It is profit before Vertex Pharmaceuticals operating expenses, interest payments and taxes. Gross profit is also known as gross margin. The profit a company makes after deducting the costs associated with making and selling its products, or the costs associated with providing its services.Other Operating Expenses
Other Operating Expenses is the expense which generally does not depend on sales or production quantities of Vertex Pharmaceuticals. It is also known as Vertex Pharmaceuticals overhead expenses. Typically these expenses include marketing, rent and utilities, office, leases, and other overhead cost. Expenses incurred from non-core business activities, including administrative and general expenses, but excluding costs directly related to production.Most accounts from Vertex Pharmaceuticals' income statement are interrelated and interconnected. However, analyzing income statement accounts one by one will only give a small insight into Vertex Pharmaceuticals current financial condition. On the other hand, looking into the entire matrix of income statement accounts, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out World Market Map to better understand how to build diversified portfolios, which includes a position in Vertex Pharmaceuticals. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in estimate. For more information on how to buy Vertex Stock please use our How to Invest in Vertex Pharmaceuticals guide.At this time, Vertex Pharmaceuticals' Cost Of Revenue is fairly stable compared to the past year. Income Before Tax is likely to rise to about 4.6 B in 2024, whereas Interest Expense is likely to drop slightly above 28.9 M in 2024.
2021 | 2022 | 2023 | 2024 (projected) | Gross Profit | 6.7B | 7.9B | 8.6B | 9.0B | Total Revenue | 7.6B | 8.9B | 9.8B | 10.3B |
Vertex Pharmaceuticals income statement Correlations
Click cells to compare fundamentals
Vertex Pharmaceuticals Account Relationship Matchups
High Positive Relationship
High Negative Relationship
Vertex Pharmaceuticals income statement Accounts
2019 | 2020 | 2021 | 2022 | 2023 | 2024 (projected) | ||
Total Revenue | 4.2B | 6.2B | 7.6B | 8.9B | 9.8B | 10.3B | |
Gross Profit | 3.6B | 5.5B | 6.7B | 7.9B | 8.6B | 9.0B | |
Other Operating Expenses | 3.0B | 3.3B | 4.8B | 4.6B | 6.1B | 6.4B | |
Operating Income | 1.2B | 2.9B | 2.8B | 4.3B | 3.8B | 3.9B | |
Ebit | 1.2B | 2.9B | 2.8B | 4.3B | 3.8B | 3.9B | |
Ebitda | 1.5B | 3.2B | 2.8B | 4.3B | 3.9B | 4.1B | |
Total Operating Expenses | 2.4B | 2.6B | 3.9B | 3.5B | 4.8B | 5.1B | |
Net Income | 1.2B | 2.7B | 2.3B | 3.3B | 3.6B | 3.8B | |
Income Tax Expense | 218.1M | 405.2M | 388.3M | 910.4M | 760.2M | 798.2M | |
Depreciation And Amortization | 260.3M | 331.8M | 6.7M | 37.8M | 181.3M | 190.4M | |
Cost Of Revenue | 547.8M | 736.3M | 904.2M | 1.1B | 1.3B | 1.3B | |
Income Before Tax | 1.4B | 3.1B | 2.7B | 4.2B | 4.4B | 4.6B | |
Total Other Income Expense Net | 197.4M | 260.5M | (51.7M) | (75M) | 629.6M | 661.1M | |
Research Development | 1.8B | 1.8B | 3.1B | 2.5B | 3.7B | 3.9B | |
Interest Expense | 58.5M | 58.2M | 61.5M | 54.8M | 44.1M | 28.9M | |
Selling General Administrative | 658.5M | 770.5M | 840.1M | 887.2M | 1.1B | 1.2B | |
Net Income From Continuing Ops | 1.2B | 2.7B | 2.3B | 3.3B | 3.6B | 3.8B | |
Non Operating Income Net Other | 255.9M | 318.7M | 9.8M | (20.2M) | (23.2M) | (22.1M) | |
Net Income Applicable To Common Shares | 1.2B | 2.7B | 2.3B | 3.3B | 3.8B | 4.0B | |
Tax Provision | 218.1M | 405.2M | 388.3M | 910.4M | 760.2M | 798.2M | |
Interest Income | 63.7M | 22.2M | 4.9M | 144.6M | 614.7M | 645.4M | |
Net Interest Income | 5.2M | (35.9M) | (56.6M) | 89.8M | 570.6M | 599.1M | |
Reconciled Depreciation | 106.9M | 109.5M | 125.6M | 148.3M | 181.3M | 126.6M |
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.When determining whether Vertex Pharmaceuticals offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Vertex Pharmaceuticals' financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Vertex Pharmaceuticals Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Vertex Pharmaceuticals Stock:Check out World Market Map to better understand how to build diversified portfolios, which includes a position in Vertex Pharmaceuticals. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in estimate. For more information on how to buy Vertex Stock please use our How to Invest in Vertex Pharmaceuticals guide.You can also try the Technical Analysis module to check basic technical indicators and analysis based on most latest market data.
Complementary Tools for Vertex Stock analysis
When running Vertex Pharmaceuticals' price analysis, check to measure Vertex Pharmaceuticals' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Vertex Pharmaceuticals is operating at the current time. Most of Vertex Pharmaceuticals' value examination focuses on studying past and present price action to predict the probability of Vertex Pharmaceuticals' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Vertex Pharmaceuticals' price. Additionally, you may evaluate how the addition of Vertex Pharmaceuticals to your portfolios can decrease your overall portfolio volatility.
Technical Analysis Check basic technical indicators and analysis based on most latest market data | |
Price Ceiling Movement Calculate and plot Price Ceiling Movement for different equity instruments | |
Sign In To Macroaxis Sign in to explore Macroaxis' wealth optimization platform and fintech modules | |
Watchlist Optimization Optimize watchlists to build efficient portfolios or rebalance existing positions based on the mean-variance optimization algorithm | |
Risk-Return Analysis View associations between returns expected from investment and the risk you assume | |
Earnings Calls Check upcoming earnings announcements updated hourly across public exchanges | |
Options Analysis Analyze and evaluate options and option chains as a potential hedge for your portfolios |
Is Vertex Pharmaceuticals' industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Vertex Pharmaceuticals. If investors know Vertex will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Vertex Pharmaceuticals listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Quarterly Earnings Growth 0.181 | Earnings Share 13.88 | Revenue Per Share 38.297 | Quarterly Revenue Growth 0.093 | Return On Assets 0.1317 |
The market value of Vertex Pharmaceuticals is measured differently than its book value, which is the value of Vertex that is recorded on the company's balance sheet. Investors also form their own opinion of Vertex Pharmaceuticals' value that differs from its market value or its book value, called intrinsic value, which is Vertex Pharmaceuticals' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Vertex Pharmaceuticals' market value can be influenced by many factors that don't directly affect Vertex Pharmaceuticals' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Vertex Pharmaceuticals' value and its price as these two are different measures arrived at by different means. Investors typically determine if Vertex Pharmaceuticals is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Vertex Pharmaceuticals' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.